Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Anti-podocalyxin antibody exerts antitumor effects via antibody-dependent cellular cytotoxicity in mouse xenograft models of oral squamous cell carcinoma.

Itai S, Ohishi T, Kaneko MK, Yamada S, Abe S, Nakamura T, Yanaka M, Chang YW, Ohba SI, Nishioka Y, Kawada M, Harada H, Kato Y.

Oncotarget. 2018 Apr 27;9(32):22480-22497. doi: 10.18632/oncotarget.25132. eCollection 2018 Apr 27.

2.

Antipodocalyxin Antibody chPcMab-47 Exerts Antitumor Activity in Mouse Xenograft Models of Colorectal Adenocarcinomas.

Kaneko MK, Kunita A, Yamada S, Nakamura T, Yanaka M, Saidoh N, Chang YW, Handa S, Ogasawara S, Ohishi T, Abe S, Itai S, Harada H, Kawada M, Nishioka Y, Fukayama M, Kato Y.

Monoclon Antib Immunodiagn Immunother. 2017 Aug;36(4):157-162. doi: 10.1089/mab.2017.0020. Epub 2017 Jun 30.

PMID:
28665782
3.

ChLpMab-23: Cancer-Specific Human-Mouse Chimeric Anti-Podoplanin Antibody Exhibits Antitumor Activity via Antibody-Dependent Cellular Cytotoxicity.

Kaneko MK, Nakamura T, Kunita A, Fukayama M, Abe S, Nishioka Y, Yamada S, Yanaka M, Saidoh N, Yoshida K, Fujii Y, Ogasawara S, Kato Y.

Monoclon Antib Immunodiagn Immunother. 2017 Jun;36(3):104-112. doi: 10.1089/mab.2017.0014. Epub 2017 May 15.

PMID:
28504613
4.

Antitumor activity of chLpMab-2, a human-mouse chimeric cancer-specific antihuman podoplanin antibody, via antibody-dependent cellular cytotoxicity.

Kaneko MK, Yamada S, Nakamura T, Abe S, Nishioka Y, Kunita A, Fukayama M, Fujii Y, Ogasawara S, Kato Y.

Cancer Med. 2017 Apr;6(4):768-777. doi: 10.1002/cam4.1049. Epub 2017 Mar 23.

5.

Antiglycopeptide Mouse Monoclonal Antibody LpMab-21 Exerts Antitumor Activity Against Human Podoplanin Through Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity.

Kato Y, Kunita A, Fukayama M, Abe S, Nishioka Y, Uchida H, Tahara H, Yamada S, Yanaka M, Nakamura T, Saidoh N, Yoshida K, Fujii Y, Honma R, Takagi M, Ogasawara S, Murata T, Kaneko MK.

Monoclon Antib Immunodiagn Immunother. 2017 Feb;36(1):20-24. doi: 10.1089/mab.2016.0045.

PMID:
28234556
6.

Chimeric Anti-Human Podoplanin Antibody NZ-12 of Lambda Light Chain Exerts Higher Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity Compared with NZ-8 of Kappa Light Chain.

Kaneko MK, Abe S, Ogasawara S, Fujii Y, Yamada S, Murata T, Uchida H, Tahara H, Nishioka Y, Kato Y.

Monoclon Antib Immunodiagn Immunother. 2017 Feb;36(1):25-29. doi: 10.1089/mab.2016.0047. Epub 2017 Feb 3.

PMID:
28157429
7.

Development and characterization of anti-glycopeptide monoclonal antibodies against human podoplanin, using glycan-deficient cell lines generated by CRISPR/Cas9 and TALEN.

Kaneko MK, Nakamura T, Honma R, Ogasawara S, Fujii Y, Abe S, Takagi M, Harada H, Suzuki H, Nishioka Y, Kato Y.

Cancer Med. 2017 Feb;6(2):382-396. doi: 10.1002/cam4.954. Epub 2017 Jan 19.

8.

Antitumor effect of novel anti-podoplanin antibody NZ-12 against malignant pleural mesothelioma in an orthotopic xenograft model.

Abe S, Kaneko MK, Tsuchihashi Y, Izumi T, Ogasawara S, Okada N, Sato C, Tobiume M, Otsuka K, Miyamoto L, Tsuchiya K, Kawazoe K, Kato Y, Nishioka Y.

Cancer Sci. 2016 Sep;107(9):1198-205. doi: 10.1111/cas.12985. Epub 2016 Aug 25.

9.

The chimeric antibody chLpMab-7 targeting human podoplanin suppresses pulmonary metastasis via ADCC and CDC rather than via its neutralizing activity.

Kato Y, Kunita A, Abe S, Ogasawara S, Fujii Y, Oki H, Fukayama M, Nishioka Y, Kaneko MK.

Oncotarget. 2015 Nov 3;6(34):36003-18. doi: 10.18632/oncotarget.5339.

10.

A novel targeting therapy of malignant mesothelioma using anti-podoplanin antibody.

Abe S, Morita Y, Kaneko MK, Hanibuchi M, Tsujimoto Y, Goto H, Kakiuchi S, Aono Y, Huang J, Sato S, Kishuku M, Taniguchi Y, Azuma M, Kawazoe K, Sekido Y, Yano S, Akiyama S, Sone S, Minakuchi K, Kato Y, Nishioka Y.

J Immunol. 2013 Jun 15;190(12):6239-49. doi: 10.4049/jimmunol.1300448. Epub 2013 May 20.

11.

Chimeric anti-podoplanin antibody suppresses tumor metastasis through neutralization and antibody-dependent cellular cytotoxicity.

Kaneko MK, Kunita A, Abe S, Tsujimoto Y, Fukayama M, Goto K, Sawa Y, Nishioka Y, Kato Y.

Cancer Sci. 2012 Nov;103(11):1913-9. doi: 10.1111/j.1349-7006.2012.02385.x. Epub 2012 Aug 27.

Supplemental Content

Loading ...
Support Center